Arena Pharma (ARNA) Income Statement

Click line-items for a historical chart and %

Manufacturing services
Collaborative agreements	12.95M
Total revenues	19.24M
Cost of manufacturing services
Research and development	17.47M
General and administrative	8.59M
Restructuring charges	231K
Amortization of acquired technology and other intangibles
Total operating expenses	29.1M
Loss from operations	-9.86M
Interest income	54K
Interest expense	-1.61M
Gain from valuation of derivative liabilities	0
Loss on extinguishment of debt
Other	-1.07M
Total interest and other expense, net	-2.62M
Net loss	-12.36M
Deemed dividend related to beneficial conversion feature of convertible preferred stock
Net loss allocable to common stockholders
Net loss per share allocable to common stockholders, basic	-0.05
Net loss per share allocable to common stockholders, diluted	-0.05
Shares used in calculating net loss per share allocable to common stockholders, basic	243.25M
Shares used in calculating net loss per share allocable to common stockholders, diluted	243.25M

Entities mentioned with ARNA

View All Entities